Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Medical Officer | February 22, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 22, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,111 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Sale · Disposed 14,568 · Balance 250,111 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 27, 2024 00:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 14,568 | $10.05 | $146,344.30 |
DisclosureSEC source: 0001628280-24-006982 · wk-form4_1708993886.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,111 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 23:56 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,321 | $10.24 | $34,005.71 |
DisclosureSEC source: 0001628280-24-005418 · wk-form4_1708127793.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,679 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,591 | $1.53 Strike: $1.53 | $72,814.23 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,591 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,576 | $1.58 Strike: $1.58 | $21,382.20 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,576 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,833 | $0.86 Strike: $0.86 | $16,102.22 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,833 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 47,591 | $1.53 | $72,814.23 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 13,576 | $1.58 | $21,382.20 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 18,833 | $0.86 | $16,102.22 |
DisclosureSEC source: 0001628280-24-000169 · wk-form4_1704311270.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-23-035409 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $25.95 | $129,727.00 |
DisclosureSEC source: 0001209191-23-035409 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.63 to $26.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-23-035409 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,400 | $23.56 | $32,984.14 |
DisclosureSEC source: 0001209191-23-013683 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.47 to $23.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 8,920 | $23.00 | $205,185.87 |
DisclosureSEC source: 0001209191-23-013683 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.47 to $23.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,878 | $25.97 | $74,750.29 |
DisclosureSEC source: 0001209191-23-012996 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,320 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001209191-23-012996 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012996 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,198 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,802 | $25.29 | $70,856.98 |
DisclosureSEC source: 0001209191-23-011384 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,198 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 01:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,594 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-23-004945 · doc4.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,535 Underlying: Common Stock · 4,594 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 01:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,406 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-004945 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,576 Underlying: Common Stock · 25,406 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 01:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 30,000 | $30.00 | $900,057.00 |
DisclosureSEC source: 0001209191-23-004945 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 01:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 4,594 | $5.18 | $23,773.95 |
DisclosureSEC source: 0001209191-23-004945 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 01:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 25,406 | $1.58 | $40,014.45 |
DisclosureSEC source: 0001209191-23-004945 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,406 Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-22-042844 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,982 Underlying: Common Stock · 5,000 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001209191-22-042844 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 5,000 | $1.58 | $7,875.00 |
DisclosureSEC source: 0001209191-22-042844 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 21:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,991 | $24.89 | $124,209.02 |
DisclosureSEC source: 0001209191-22-038737 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.55 to $25.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2022 Filed Jun 22, 2022 21:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 7,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038737 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,991 Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-012954 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2032-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 67,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012954 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,768 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,009 | $31.93 | $96,079.78 |
DisclosureSEC source: 0001209191-22-011338 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,768 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-011338 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $31.54 | $157,700.00 |
DisclosureSEC source: 0001209191-22-011338 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-22-011338 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-007235 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $34.52 | $172,619.50 |
DisclosureSEC source: 0001209191-22-007235 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.13 to $35.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-22-007235 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 22:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-004143 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 22:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,542 | $35.52 | $90,290.06 |
DisclosureSEC source: 0001209191-22-004143 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.13 to $35.865 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 22:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,458 | $34.59 | $85,014.11 |
DisclosureSEC source: 0001209191-22-004143 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,319 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.12 to $35.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 22:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-22-004143 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 00:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-002257 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,591 Underlying: Common Stock · 5,000 shares Expires 2018-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 00:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 400 | $37.78 | $15,112.00 |
DisclosureSEC source: 0001209191-22-002257 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 00:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,600 | $37.14 | $170,844.00 |
DisclosureSEC source: 0001209191-22-002257 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,177 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.76 to $37.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 00:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-22-002257 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,591 Underlying: Common Stock · 5,000 shares Expires 2018-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,200 | $52.20 | $62,640.48 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.01 to $52.59 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,034 | $51.30 | $53,039.75 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,977 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,050 | $50.60 | $53,133.15 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.9825 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,716 | $49.41 | $84,794.77 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,061 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.91 to $49.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.